ERBB2 and breast cancer: In the SERENA‐2 trial, camizestrant, a next‐generation oral selective estrogen receptor antagonist and degrader (ngSERD), is being studied with promising results in post‐menopausal women with advanced ER‐positive/HER2‐negative BC.